ArticleFrontiers in pharmacology2025
Interaction of blood-entry components, network pharmacology and transcriptomics to elucidate the mechanism of Wentong plaster in treating primary dysmenorrhea.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A novelFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary dysmenorrhea (PD) is characterized by pain during the menstrual cycle, affects women's health. Our group developed a traditional Chinese medicine plaster (Wentong plaster, WTT) for the treatment of PD. However, the underlying mechanisms have not yet been elucidated. Methods: In this study, the blood-entry components of WTT were detected using UPLC-Q-Exactive Orbitrap-MS, and the therapeutic functions of WTT on PD were evaluated by the writhing response, pathological analysis, and the levels of estrogen, nitric oxide, progesterone, among other indicators. Network pharmacology and transcriptomics were used to elucidate the underlying mechanisms. Finally, enzyme-linked immunosorbent assay and western blotting were used to determine the levels of relevant indicators. Results: Our findings indicate that 49 original blood-entry components were detected. Meanwhile, WTT upregulated the level of NO, and downregulated the levels of PGF2α, PGE2, estrogen, and progesterone, thereby increasing blood flow, alleviating inflammatory responses, and inhibiting the writhing response. Results from network pharmacology and transcriptomics analyses indicated that WTT could increase the expression of Lcn2 and decrease the expression of Cxcl6 and IL-17, thereby regulating the IL-17 signaling pathway, and alleviating inflammation to treat PD. Conclusion: WTT mainly down-regulates the levels of Cxcl6 and IL-17 and up-regulates the expression of Lcn2, further regulates the IL-17 signaling pathway to alleviate inflammation, ultimately treating PD. This study provides a basis for further research on the mechanism of WTT, and offers a reference for its clinical application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.